Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 17/20 | 0.64 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.60 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.60 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.60 |
| ▸ | RAF1 | P04049 | 2/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | GCGR | P47871 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30220460 | 0.96 | TEK (0.70) | TEKMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL17835458 | 0.96 | TEK (0.70) | TEKMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL30220453 | 0.96 | TEK (0.70) | TEKMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4552055 | 0.86 | MAPK14 (0.76) | TEKMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6926311 | 0.83 | TEK (0.65) | TEKMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6447875 | 0.80 | MAPK13 (0.72) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL17847345 | 0.80 | TEK (0.73) | TEKMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL15075611 | 0.80 | MAPK13 (0.89) | TEKMAPK13MAPK12MAPK11MAPK14 | |
| Sb-203580 SCHEMBL146399 | 0.79 | MAPK11 (0.75) | TEKMAPK13MAPK12MAPK11MAPK14 | |
| Sb-203580 SCHEMBL95208 | 0.79 | MAPK11 (0.75) | TEKMAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349880-A1 | ADOPTIVE IMMUNOTHERAPY FOR TREATING CANCER | Université de Lausanne (CH) | 2017-12-07 | — | — | US | claimed |
| EP-3233114-A1 | ADOPTIVE IMMUNOTHERAPY FOR TREATING CANCER | Université de Lausanne (CH) | 2017-10-25 | — | — | EP | claimed |
| WO-2016096903-A1 | ADOPTIVE IMMUNOTHERAPY FOR TREATING CANCER | Université de Lausanne (CH) | 2016-06-23 | — | — | WO | claimed |
| US-10858626-B2 | Adoptive immunotherapy for treating cancer | Université de Lausanne (CH) | 2020-12-08 | — | — | US | disclosed |
| US-20170349880-A1 | ADOPTIVE IMMUNOTHERAPY FOR TREATING CANCER | Université de Lausanne (CH) | 2017-12-07 | — | — | US | disclosed |
| EP-3233114-A1 | ADOPTIVE IMMUNOTHERAPY FOR TREATING CANCER | Université de Lausanne (CH) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016096903-A1 | ADOPTIVE IMMUNOTHERAPY FOR TREATING CANCER | Université de Lausanne (CH) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349880-A1 | ADOPTIVE IMMUNOTHERAPY FOR TREATING CANCER | ICOS, IL2, PBK | TEK 40/4885MAPK13 4691/4885MAPK12 3994/4885 |
| US-10858626-B2 | Adoptive immunotherapy for treating cancer | ICOS, IL2, PBK | TEK 40/4885MAPK13 4691/4885MAPK12 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.